The Potential Role of Antidiabetic Agents in Bipolar Disorder
Current Treatment Options in Psychiatry · 03.03.2026 · 13 (1)
DOI: 10.1007/s40501-026-00375-2 ↗Kurz gefasst
Fachartikel in der Zeitschrift Current Treatment Options in Psychiatry, online erschienen am 03.03.2026. Verfasst von Eliana Landivar und 3 weiteren Autor:innen. Die Arbeit nennt 103 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Universidade De São Paulo.
Abstract (Originalsprache)
Purpose of review This narrative review aims to summarize the evidence supporting the use of antidiabetic agents as potential adjunctive treatments in bipolar disorder (BD). The focus is on the shared pathophysiological mechanisms linking insulin resistance (IR) and BD, and on how metabolic modulation may influence mood, cognition, and treatment outcomes. Recent findings Emerging research indicates that IR and related metabolic abnormalities are highly prevalent in BD and are associated with illness progression, cognitive impairment, and reduced treatment response. Studies involving metformin, pioglitazone, glucagon-like peptide-1 (GLP-1) receptor agonists (such as liraglutide and semaglutide), and sodium–glucose cotransporter 2 (SGLT2) inhibitors (such as empagliflozin) have demonstrated improvements in depressive symptoms, metabolic parameters, and neuroinflammatory markers in individuals with mood disorders. Mechanistic evidence suggests that these agents may exert neuroprotective effects by enhancing insulin signaling, reducing oxidative stress, and improving mitochondrial and synaptic function. Nevertheless, the available studies are limited by small sample sizes and short follow-up durations. Summary Targeting IR represents a promising translational approach for improving both metabolic and psychiatric outcomes in BD. Future research should prioritize mechanistic studies and randomized controlled trials designed to clarify optimal dosing, treatment duration, and patient selection, as bridging psychiatry and endocrinology through metabolic interventions could redefine treatment paradigms for bipolar disorder.
Förderung
- Universidade De São Paulo
Zitieren
APA
Landivar, E., Gabriel, F. C., Daolio, L. D., & Lafer, B. (2026). The Potential Role of Antidiabetic Agents in Bipolar Disorder. Current Treatment Options in Psychiatry, 13(1). https://doi.org/10.1007/s40501-026-00375-2
Vancouver
Landivar E, Gabriel FC, Daolio LD, Lafer B. The Potential Role of Antidiabetic Agents in Bipolar Disorder. Current Treatment Options in Psychiatry. 2026;13(1). doi:10.1007/s40501-026-00375-2
BibTeX
@article{Landivar2026,
author = {Landivar, Eliana and Gabriel, Fernanda C. and Daolio, Luísa D. and Lafer, Beny},
title = {The Potential Role of Antidiabetic Agents in Bipolar Disorder},
journal = {Current Treatment Options in Psychiatry},
year = {2026},
volume = {13},
number = {1},
doi = {10.1007/s40501-026-00375-2}
}
EUVIMED